Jessica Leung1, Kathleen E Sullivan2, Ludmila Perelygina3, Joseph P Icenogle3, Ramsay L Fuleihan4, Tatiana M Lanzieri3. 1. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS A-34, Atlanta, GA, 30333, USA. JLeung@cdc.gov. 2. Division of Allergy Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. 3. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS A-34, Atlanta, GA, 30333, USA. 4. Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern Medicine, Chicago, IL, 60611, USA.
Abstract
PURPOSE: Granulomas are a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD. METHODS: We used the Truven Health MarketScan® 2005-2015 Commercial Claims and Encounters and 2006-2015 Medicaid databases and the US Immunodeficiency Network (USIDNET) PIDD registry (a program of the Immune Deficiency Foundation). Our study population consisted of persons age < 65 years with PIDD, defined as persons with ≥ 2 claims with a diagnostic code for PIDD in MarketScan databases, or patients enrolled in USIDNET. Granulomas were identified using diagnostic codes in MarketScan or provider report in USIDNET. We calculated annual prevalence of PIDD and of granulomas among PIDD patients. RESULTS: We identified 247,474 and 40,395 persons with PIDD among commercially and Medicaid-insured persons, respectively. PIDD prevalence was 6.0/10,000 in 2005 and 11.7/10,000 in 2015 among commercially insured persons and 5.5/10,000 in 2006 and 9.6/10,000 in 2015 among Medicaid-insured persons. The prevalence of granulomas among PIDD patients was 1.2 and 1.5% among commercially and Medicaid-insured persons, respectively. In USIDNET, prevalence of granulomas was 4.4% (177/4021). The proportion with granulomas was similar across age groups in MarketScan, but varied from 2 to 9% in USIDNET. The reported prevalence of granulomas differed depending on PIDD condition: 1-2% in the MarketScan data and 0-13% in USIDNET. CONCLUSION: Granuloma prevalence in PIDD patients was 1-4%. Our study provides an estimate of the proportion of PIDD patients and suggests that granulomas are an uncommon occurrence among patients with PIDD.
PURPOSE:Granulomas are a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD. METHODS: We used the Truven Health MarketScan® 2005-2015 Commercial Claims and Encounters and 2006-2015 Medicaid databases and the US Immunodeficiency Network (USIDNET) PIDD registry (a program of the Immune Deficiency Foundation). Our study population consisted of persons age < 65 years with PIDD, defined as persons with ≥ 2 claims with a diagnostic code for PIDD in MarketScan databases, or patients enrolled in USIDNET. Granulomas were identified using diagnostic codes in MarketScan or provider report in USIDNET. We calculated annual prevalence of PIDD and of granulomas among PIDD patients. RESULTS: We identified 247,474 and 40,395 persons with PIDD among commercially and Medicaid-insured persons, respectively. PIDD prevalence was 6.0/10,000 in 2005 and 11.7/10,000 in 2015 among commercially insured persons and 5.5/10,000 in 2006 and 9.6/10,000 in 2015 among Medicaid-insured persons. The prevalence of granulomas among PIDD patients was 1.2 and 1.5% among commercially and Medicaid-insured persons, respectively. In USIDNET, prevalence of granulomas was 4.4% (177/4021). The proportion with granulomas was similar across age groups in MarketScan, but varied from 2 to 9% in USIDNET. The reported prevalence of granulomas differed depending on PIDD condition: 1-2% in the MarketScan data and 0-13% in USIDNET. CONCLUSION:Granuloma prevalence in PIDD patients was 1-4%. Our study provides an estimate of the proportion of PIDD patients and suggests that granulomas are an uncommon occurrence among patients with PIDD.
Entities:
Keywords:
Granulomas; MarketScan; PIDD; Primary immunodeficiency disorders; USIDNET registry; United States
Authors: Ludmila Perelygina; Stanley Plotkin; Pierre Russo; Timo Hautala; Francisco Bonilla; Hans D Ochs; Avni Joshi; John Routes; Kiran Patel; Claudia Wehr; Joseph Icenogle; Kathleen E Sullivan Journal: J Allergy Clin Immunol Date: 2016-09-06 Impact factor: 10.793
Authors: Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; Sung-Yun Pai; Barbara Ballard; Sarah C Bauer; Jack J H Bleesing; Marcia Boyle; Amy Brower; Rebecca H Buckley; Mirjam van der Burg; Lauri M Burroughs; Fabio Candotti; Andrew J Cant; Talal Chatila; Charlotte Cunningham-Rundles; Mary C Dinauer; Christopher C Dvorak; Alexandra H Filipovich; Thomas A Fleisher; Hubert Bobby Gaspar; Tayfun Gungor; Elie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary Hurley; Sumathi Iyengar; Elizabeth M Kang; Brent R Logan; Janel R Long-Boyle; Harry L Malech; Sean A McGhee; Fred Modell; Vicki Modell; Hans D Ochs; Richard J O'Reilly; Robertson Parkman; David J Rawlings; John M Routes; William T Shearer; Trudy N Small; Heather Smith; Kathleen E Sullivan; Paul Szabolcs; Adrian Thrasher; Troy R Torgerson; Paul Veys; Kenneth Weinberg; Juan Carlos Zuniga-Pflucker Journal: J Allergy Clin Immunol Date: 2013-10-15 Impact factor: 10.793
Authors: Angela Berkhout; Kahn Preece; Vanil Varghese; Vinita Prasad; Helen Heussler; Julia Clark; Sophie C H Wen Journal: Ther Adv Vaccines Immunother Date: 2020-10-16
Authors: Ludmila Perelygina; Raeesa Faisthalab; Emily Abernathy; Min-Hsin Chen; LiJuan Hao; Lionel Bercovitch; Diana K Bayer; Lenora M Noroski; Michael T Lam; Maria Pia Cicalese; Waleed Al-Herz; Arti Nanda; Joud Hajjar; Koen Vanden Driessche; Shari Schroven; Julie Leysen; Misha Rosenbach; Philipp Peters; Johannes Raedler; Michael H Albert; Roshini S Abraham; Hemalatha G Rangarjan; David Buchbinder; Lisa Kobrynski; Anne Pham-Huy; Julie Dhossche; Charlotte Cunningham Rundles; Anna K Meyer; Amy Theos; T Prescott Atkinson; Amy Musiek; Mehdi Adeli; Ute Derichs; Christoph Walz; Renate Krüger; Horst von Bernuth; Christoph Klein; Joseph Icenogle; Fabian Hauck; Kathleen E Sullivan Journal: Front Immunol Date: 2021-12-20 Impact factor: 7.561